NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
16 sept. 2024 08h05 HE
|
NextCure
Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism...
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
01 août 2024 16h05 HE
|
NextCure
LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected...
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
20 juin 2024 16h10 HE
|
NextCure
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
30 mai 2024 16h05 HE
|
NextCure
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3...
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
02 mai 2024 16h05 HE
|
NextCure
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0...
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
24 avr. 2024 16h05 HE
|
NextCure
NextCure, Inc. (Nasdaq: NXTC) will present phase 1b data of NC410 in combination with pembrolizumab at ASCO 2024.
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
08 avr. 2024 07h00 HE
|
NextCure
BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
04 avr. 2024 07h05 HE
|
NextCure
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 07h00 HE
|
NextCure
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
21 mars 2024 08h55 HE
|
NextCure
Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts...